Trial Profile
A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs DPX E7 (Primary)
- Indications Anal cancer; Cervical cancer; Head and neck cancer; Oropharyngeal cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- 10 Jan 2024 Primary end point is updated to add one more safety end point and a new efficacy end point, thus making "TU" also a trial focus. Timeline for previously existing safety end-point is decreased from 2 years to approximately 2 months.
- 18 Feb 2022 Planned End Date changed from 1 May 2023 to 1 Dec 2023.
- 18 Feb 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.